AstraZeneca and MSD's PARP inhibitor Lynparza has improved long-term survival when given as adjuvant therapy for early breast ...

Domestic pharma valuations are rich in the context of long-term risks, such as slower growth and regulatory interventions, ...

Indian pharmaceutical companies, which benefited from sector tailwinds such as stable generic pricing and shortage-led ...

A U.S. appeals court ruled that Novartis can't prevent MSN Pharmaceuticals' proposed generic of heart drug Entresto.

Glenmark Pharmaceuticals issued seven recalls for pills that didn’t dissolve properly, records show. All were made at the same factory in India. But the FDA still hasn’t stopped the company from ...

The Pharmaceutical Market, valued at an impressive USD 1.5 trillion in 2022, is poised for remarkable growth, with ...

Zeno Health launches 181st medical store, expands its product portfolio: Our Bureau, Mumbai Thursday, December 12, 2024, ...

Giving Boots the boot would be one obvious way to raise cash. Walgreens tried to offload the UK drugstore chain back in 2022. But the sale process was abandoned after the upheaval in credit markets ...

The program will continue for a minimum of three years to ensure reliable and continuous supply to these patients. In ...

On 11 December 2024, the High Court handed down its judgment in Commonwealth of Australia v Sanofi [2024] HCA 47, bringing the long-running damages dispute between the Commonwealth and Sanofi to an ...

Pharmaceutical and biotech businesses were enthusiastic about the UPC before the court opened, but so far there has only been ...

目前，欧美发达国家和地区凭借创新药研发、生产工艺改进及知识产权保护等优势，在高附加值的专利原料药领域占据主导地位；印度以仿制药产业拉动特色原料药生产；中国以技术成熟、市场需求大的大宗原料药为主。